Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01470066
Other study ID # PET2005-01
Secondary ID
Status Recruiting
Phase N/A
First received November 3, 2011
Last updated November 10, 2011
Start date August 2004
Est. completion date May 2012

Study information

Verified date September 2005
Source Chonnam National University Hospital
Contact Deok-Hwan Yang, M.D., Ph.D.
Phone 82-61-379-7636
Email drydh1685@gmail.com
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), the positive predictive value (PPV) of interim PET/CT scanning has not been determined in patients with peripheral T cell lymphoma (PTCL). The sequential interim PET/CT will be prospectively investigated to determine whether it provided additional prognostic information and could be a positive predictable value for the treatment of PTCL.


Description:

1. Treatment protocol

- Patients with limited-stage (stage I/II) are treated with CHOP/CHOP-like chemotherapy [cyclophosphamide 750 mg/m2 i.v. on D1, vincristine 1.4 mg/m2 i.v. on D1, doxorubicin 50 mg/m2 i.v. on D1, and prednisolone 60 mg/m2 p.o. on D1-5] in standard doses every three weeks and three to four cycles of CHOP/CHOP-like chemotherapy followed by involved field radiation therapy (IFRT, 30 Gy). Patients with advanced-stage (stage III/IV) are treated with eight cycles of primary chemotherapy and patients greater than 65 years and/or those with a frail general condition were treated with only six cycles of primary chemotherapy if they achieved a complete response (CR) for the interim response.

2. Response evaluation based on three parameters of visual, standard uptake value(SUV)-based and metabolic tumor volume (MTV)-based assessments

- We firstly classify patients with five-point scale (5-PS) by the interim PET/CT analysis based on the Deauville criteria12: 1, No uptake; 2, uptake ≤ mediastinum; 3, uptake > mediastinum but ≤ liver; 4, uptake moderately increased compared to the liver uptake at any site; 5, markedly increased uptake compared to the liver at any site and new sites or/and new sites of disease. Interim PET/CT image are graded as negative or positive by comparison of initial PET/CT and grade 1-3 considered as negative and grade 4-5 considered for positive.19 This grading process is independent of the size of the residual tumor.

Secondly, we classify the patients with the quantitative analysis of 18F-FDG uptake changes based on the percentage of SUVmax reduction between initial and interim PET/CT. On axial, coronal, or sagittal coregistered PET/CT slices, simple circular regions of interest (ROIs) were placed so as to cover the lesion or background. SUV measurements are corrected for body weight according to the following standard formula: Mean ROI activity (MBq/ml)

- [Injected dose (MBq)/Body weight (kg)].20 For each PET dataset, the maximum SUV (SUVmax) is defined as the highest SUV among all hypermetabolic tumor foci. SUVmax reduction rate (ΔSUVmax) is calculated as following:

ΔSUVmax (%) = 100 x [SUVmax (initial) - SUVmax (interim)]/SUVmax (initial)

If all lesions had disappeared on interim PET, ROI were drawn in the same area on interim PET as on baseline PET.

We finally classify the patients with the quantitative analysis of metabolic volume changes based on the percentage of MTV reduction (ΔMTV) between initial and interim PET/CT. To define the exact tumor margins around the target lesions, SUV2.5 is used as following previous reports, which means that the tumor volume area in PET/CT is delineated by a circle encompassing regions with SUV cutoff value of 2.5.16,21 The MTV2.5 is measured using AW Volume ShareTM workstation (GE Healthcare) on the fused PET/CT images.17 AW Volume ShareTM allows automatic registration and fusion between two volumetric acquisitions, which come from different acquisition modalities. The active MTV2.5 are measured in a 3-D manner by selecting volume of interest (VOI) on the axial image, and the size of VOI is manually regulated on the corresponding coronal and sagittal images to include entire active tumors in the VOI. The SUVmax and the sum of the tumor volumes in all hypermetabolic tumor foci were computed automatically by the program. The MTV2.5 reduction rate (ΔMTV2.5) is calculated as same formula as SUVmax reduction rate.

3. The response assessments of interim PET/CT scans

- will be assessed based on the combination with three parameters of the Deauville five-point scale (5-PS), the reduction rate of maximal standardized uptake value (ΔSUVmax), and the reduction rate of metabolic tumor volume (ΔMTV2.5) in PTCLs


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date May 2012
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age above 18 years

2. Histologically proven PTCLs except primary cutaneous/subcutaneous panniculitis

3. ECOG performance status = 2

4. Patients who are available to be performed PET/CT at diagnosis

5. No severe concomitant disease

Exclusion Criteria:

1. Patients who did not undergo PET/CT scans at diagnosis

2. Patients who have a primary CNS lymphoma

3. Patients who have a HIV or HTLV-1

4. Patients who could not receive primary chemotherapy

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Locations

Country Name City State
Korea, Republic of Chonnam National University Hwasun Hospital Hwasun-gun Jeollanam-do

Sponsors (2)

Lead Sponsor Collaborator
Chonnam National University Hospital Kyungpook National University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival Patients whose disease did not progress would be censored using the date at which they were last known to show no progress. From the treatment start time to the first recording of disease progression or death from any cause, which assessed up to 24 months. No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05559008 - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Not yet recruiting NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma Early Phase 1
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas